Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort study.

A precise definition of low disease activity (LDA) in systemic lupus erythematosus (SLE) is crucial for managing patients according to a T2T strategy.1 Lupus low disease activity state (LLDAS) was...

ObjectivesTo unveil biological milieus underlying low disease activity (LDA) and remission versus active systemic lupus erythematosus (SLE).MethodsWe determined differentially expressed pathways (DEPs) in SLE patients from the PRECISESADS project (NTC02890121)...

BackgroundWomen with systemic lupus erythematosus (SLE) have a higher risk for adverse pregnancy outcomes (APOs) including preterm birth (PB) and low birth weight (LBW) [1]. These APOs are revealed to...

FRI0179 A STUDY ON THE ACHIEVEMENT OF LUPUS LOW DISEASE ACTIVITY STATE AND QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: FROM THE JUNTENDO UNIVERSITY SLE PROSPECTIVE REGISTRY STUDY

OBJECTIVESTo apply current definitions of Lupus Low Disease Activity State (LLDAS) to a large cohort and evaluate the concordance between LLDAS and the clinical status according to the expert opinion.MethodsA...

SAT0284 Both Prolonged Remission and Lupus Low Disease Activity State Are Associated with Reduced Damage Accrual in Systemic Lupus Erythematosus

FRI0167 LONG TERM CLINICAL OUTCOME IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS FOLLOWED FOR MORE THAN 20 YEARS IN THREE ITALIAN TERTIARY REFERRAL CENTERS: THE MILAN SYSTEMIC LUPUS ERYTHEMATOSUS CONSORTIUM (SMILE) COHORT

Background:Anti-ribonucleoprotein (RNP) (auto)antibodies are frequently detected in patients with systemic lupus erythematosus (SLE). Associations of RNP with SLE disease activity remain incompletely understood.Objectives:We undertook a comprehensive examination of characteristics of...

Background Systemic Lupus Erythematosus (SLE) is a heterogeneous disease that can cause multisystem inflammation and damage. There are currently no widely agreed upon targets for determining adequate disease control. Lupus Low Disease Activity State (LLDAS) is a new clinical evaluation tool that assesses low disease activity state in lupus patients (Franklyn, et al. Ann Rheum Dis. 2016; 75: 1615–1621). Our study examines the relationship between the percentage of time patients spend in LLDAS and organ damage accrual, cardiovascular events, and death. Methods We studied a prospective cohort of 246 patients with SLE during a 5 year follow-up period. Disease activity was measured using the SLE Disease Activity Index 2000 (SLEDAI-2K) and SELENA-SLEDAI physician global assessment (PGA). Cumulative organ damage was assessed at 1 year, 3 year, and 5 year intervals using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). The determination of LLDAS 50% of the time for the year after cohort entry (LLDAS-50) was done retrospectively through clinical chart review. The following criteria for LLDAS included: SLEDAI-2K 4 without major organ activity, no new disease activity, PGA (0–3) 1, prednisone 7.5 mg/day and stable dose of maintenance treatments. The longitudinal presence of carotid plaque and intima-media thickness (IMT) was measured at baseline and follow-up three years later. We determined the relationships between LLDAS, SDI, IMT, carotid plaque, and PREDICTS profile using multivariate regression analysis. Results The average age was 43.2 years for patients in LLDAS-50 and 39.5 years for those not in LLDAS-50 (p=0.03). Disease duration was 13.4 years for LLDAS 50% vs. 10.9 years for LLDAS There was no significant difference in measured IMT or plaque between patients in LLDAS-50 and those not in LLDAS-50 for the first year after baseline. However, patients in LLDAS-50 were significantly less likely to have major cardiac events (major stroke, myocardial infarction, positive stress test, angioplasty or percutaneous coronary intervention) or death compared with patients who were not in LLDAS-50, 17.1% and 31.4%, respectively (p=0.01). Conclusions With regard to damage progression, there was significantly less damage at 3 and 5 years among those in LLDAS 50% of the time during the first year after cohort entry. Interestingly, although there were no differences between IMT, presence of carotid plaque, or plaque progression at any of the three time points, there was a statistically significant difference in number of cardiovascular events or deaths in the LLDAS-50 group. This supports LLDAS as a valid predictor of lower overall and cardiovascular damage in SLE patients. Funding Source(s): NCATS Grant No: UL1TR00188 NIH Grant No: 5R01AR063754-02 Correlation Between LLDAS and Cardiovascular Events or Death. Patients in LLDAS 50% of the time suffer from significantly fewer cardiovascular events or deaths than their non-LLDAS counterparts.

BackgroundA LLDAS definition has received preliminarily validation. Achieving low disease activity by this definition is associated with protection from damage accrual for patients (pts) with SLE.1 However, it has not...

Background:Achievement and maintenance of the Lupus Low Disease Activity State (LLDAS) are necessary for the long-term prevention of organ damage progression in patients with systemic lupus erythematosus (SLE); however, minor...

In chronic inflammatory diseases such as rheumatoid arthritis, attainment of a specific cut-off of low (or even absent) disease activity has been associated with favourable long-term disease outcomes. Systemic lupus...

Background: Systemic Lupus Erythematosus (SLE) is an autoimmune disease with heterogeneous clinical manifestations including fatigue. Previous studies aimed at proving the relationship between fatigue and SLE disease activity showed conflicting results. In 2015, Asia Pacific Lupus Collaboration (APLC) developed low disease activity criteria, named Lupus Low Disease Activity State (LLDAS). Patients who spend more time in LLDAS have significantly lower morbidity. This study aimed to evaluate the association between disease activity based on LLDAS and fatigue. 
 Methods: This is a analytical cross-sectional study. Subjects were SLE patients at rheumatology clinic in Dr. Hasan Sadikin Hospital, Bandung during June-January 2018. Subjects were evaluated based on LLDAS criteria and divided into 2 groups: LLDAS and non-LLDAS. Fatigue status of the subjects was assessed with Fatigue Severity Scale (FSS).
 Results: A hundred and thirty-three subjects were included in this study, divided into 63 subjects in LLDAS group and 60 subjects in non-LLDAS group. Nineteen subjects (30.2%) in LLDAS group had fatigue and 39 subjects (65%) in non-LLDAS had fatigue. There was a significant association between LLDAS and fatigue (p< 0.001). Nonetheless, fatigue level in LLDAS group was still high since disease activity was not the only factor related to fatigue. Fatigue may be a distinct clinical manifestation of neuropsychiatric lupus and may be independent of lupus disease activity
 Conclusions: There was a significant association between LLDAS and fatigue showed by lower fatigue level was found in the LLDAS group than in the non-LLDAS group.
 
 Keywords: Systemic lupus erythematosus, disease activity, Lupus Low Disease Activity State, fatigue

OP0251 Attainment of low disease activity and remission in systemic lupus erythematosus patients with high disease activity in the atacicept phase iib address ii study and its long-term extension

ObjectivesTo identify the potential predictors of a lupus low disease activity state (LLDAS), and the relationship between LLDAS and disease flare, organ damage, and quality of life in Korean patients...